Fate Therapeutics
Skip to content
About Us
Overview
Leadership
Corporate Responsibility
Pipeline
Overview
Product Candidates
FT819
FT825
FT836
FT839
FT522
Early/Expanded Access Policy
Science
Our Cells of Interest
iPSC Platform
Manufacturing
Publications & Presentations
Patients
Our Commitment
Our Therapy
Autoimmune Disease
Cancer
Clinical Trials
Collaborations
Careers and Culture
The Fate Way
Join Our Team
Investors
About Fate
Press Releases
Events & Presentations
Financials & Filings
SEC Filings
Annual Reports and Proxies
Corporate Governance
Stock Information
Historical Stock Lookup
Investors FAQs
Contact
Children’s Hospital Los Angeles Division Of Rheumatology
About Us
Overview
Leadership
Corporate Responsibility
Pipeline
Overview
Product Candidates
FT819
FT825
FT836
FT839
FT522
Early/Expanded Access Policy
Science
Our Cells of Interest
iPSC Platform
Manufacturing
Publications & Presentations
Patients
Our Commitment
Our Therapy
Autoimmune Disease
Cancer
Clinical Trials
Collaborations
Careers and Culture
The Fate Way
Join Our Team
Investors
About Fate
Press Releases
Events & Presentations
Financials & Filings
SEC Filings
Annual Reports and Proxies
Corporate Governance
Stock Information
Historical Stock Lookup
Investors FAQs
Contact
Children’s Hospital Los Angeles Division Of Rheumatology
MENU
About Us
Overview
Leadership
Corporate Responsibility
Pipeline
Overview
Product Candidates
FT819
FT825
FT836
FT839
FT522
Early/Expanded Access Policy
Science
Our Cells of Interest
iPSC Platform
Manufacturing
Publications & Presentations
Patients
Our Commitment
Our Therapy
Autoimmune Disease
Cancer
Clinical Trials
Collaborations
Careers and Culture
The Fate Way
Join Our Team
Investors
About Fate
Press Releases
Events & Presentations
Financials & Filings
SEC Filings
Annual Reports and Proxies
Corporate Governance
Stock Information
Historical Stock Lookup
Investors FAQs
Contact